THE 340B PROGRAM: A FEDERAL PROGRAM IN DESPERATE NEED OF REVISION AFTER TWO-AND-A-HALF DECADES OF UNCERTAINTY.
- Published in:
- Journal of Health Care Law & Policy, 2019, v. 22, n. 2, p. 25
- By:
- Publication type:
- Article
Works matching IS 1097-4768 AND VI 22 AND IP 2 AND DT 2019
Results: 5
1
2
STATE AND FEDERAL POLICY SOLUTIONS TO RISING PRESCRIPTION DRUG PRICES IN THE U.S.
- Published in:
- Journal of Health Care Law & Policy, 2019, v. 22, n. 2, p. 15
- By:
- Publication type:
- Article
3
SERIOUS SIDE EFFECTS MAY OCCUR: THE PAINFUL SYMPTOMS OF EVOLVING TORT LIABILITY.
- Published in:
- Journal of Health Care Law & Policy, 2019, v. 22, n. 2, p. 99
- By:
- Publication type:
- Article
4
SANDOZ INC. V. AMGEN INC.: REMOVING BARRIERS TO MARKET ACCESS FOR BIOSIMILAR MANUFACTURERS.
- Published in:
- Journal of Health Care Law & Policy, 2019, v. 22, n. 2, p. 75
- By:
- Publication type:
- Article
5
2018 STUART ROME LECTURE: ORIGINS OF AND POTENTIAL SOLUTIONS TO HIGH PRESCRIPTION DRUG PRICES IN THE U.S.
- Published in:
- Journal of Health Care Law & Policy, 2019, v. 22, n. 2, p. 1
- By:
- Publication type:
- Article